ProMIS reports positive six-month interim safety, biomarker data for PMN310 in Phase 1b Alzheimer’s trial

Reuters2026/07/28 10:03

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ProMIS Neurosciences released blinded six-month interim safety and biomarker data from its PRECISE-AD Phase 1b trial of PMN310.
Interim readout showed a favorable safety profile, with no edema-type brain imaging abnormalities reported, including in higher-risk genetic subgroups.
Biomarkers moved in a direction consistent with drug target engagement, though the study remains blinded and no efficacy conclusion was drawn.
Unblinded 12-month topline results, including efficacy data, are scheduled for presentation in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ProMIS reports positive six-month interim safety, biomarker data for PMN310 in Phase 1b Alzheimer’s trial

You may also like

Crypto prices